Debate Session
Innovative funding for SMEs in Europe

Thursday April 6th from 03:30 pm to 04:30 pm - Main stage

Debate session co-organized with:
How does an innovative and ambitious Small and Medium-sized Enterprise (SME) succeed in accessing EU funds in the field of health research? The answer is given during this session not only by policy makers, but also by a Horizon 2020 SME Instrument French beneficiary. With the difficulties in obtaining early stage life sciences funding from venture capital, the role of public funding for healthcare research SMEs is becoming increasingly important. The session will provide an overview of the Horizon 2020 SME–oriented funding opportunities. Stimulating breakthrough innovation, the SME instrument is a € 3 billion euro funding program dedicated to innovative SMEs in Europe. This funding instrument, part of Horizon 2020, may offer an individual SME up to €5 million and cover 100% of its costs. For a dynamic discussion, we will bring together representatives from the European Commission, the EU Executive Agencies for SMEs and the Innovative Medicines Initiative, the world's largest public-private partnership in the area of health research. In addition, a successful biotech company will discuss how the EU funding has shaped its future in terms of scientific and commercial progress as well as the impact it has on raising investment capital. Being involved in building innovative solutions for neurophysiological research and neurofeedback applications, the French company aims to develop and validate an innovative medical device for children suffering from Attention Deficit Disorder via the EU–funded project NEWROFEED

Anna Bulzacka–Bogucka
Anna
Bulzacka–Bogucka
Philippe Cupers
Philippe
Cupers
Alexia Kefalas
Alexia
Kefalas
Pierre Meulien
Pierre
Meulien
Jean-Yves Quentel
Jean-Yves
Quentel